MedTrace Logo

Management of Ductal Carcinoma in Situ or Pure Micro-invasive Extended Breast

NCT01841749 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 228

Last updated 2025-09-12

Study results available
· View outcomes & findings →

Summary

When invasive components are discovered at mastectomy for vacuum-assisted biopsy (VAB)-diagnosed ductal carcinoma in situ (DCIS), the only option available is axillary lymph node dissection (ALND). The aim of this prospective multicenter trial was to determine the benefit of performing upfront sentinel lymph node (SLN) biopsy for these patients.

Conditions

  • Intraductal Carcinoma and Lobular Carcinoma in Situ

Interventions

PROCEDURE

sentinel node biopsy and mastectomy

sentinel node biopsy and mastectomy

Sponsors & Collaborators

  • Institut Bergonié

    lead OTHER

Principal Investigators

  • TUNON DE LARA Christine, MD · Institut Bergonié

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01841749 on ClinicalTrials.gov